Fibrosis, Liver
44
11
19
13
Key Insights
Highlights
Success Rate
93% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
2.3%
1 terminated out of 44 trials
92.9%
+6.3% vs benchmark
9%
4 trials in Phase 3/4
38%
5 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (44)
Semaglutide Treatment in the Real-world for Fibrosis Due to NAFLD in Obesity and T2DM
Liver Fibrosis in Zambian HIV-HBV Co-infected Patients
Screening for Chronic Liver Diseases in General Population
Chronic Hepatitis B Virus Infection in Zambia
Prevalence of NAFLD and Advanced Fibrosis in Patients With Type 1 Diabetes
HIBOC = Hepatic Imaging Biomarkers in Obese Children
COffee and Metabolites Modulating the Gut MicrobiomE in Colorectal caNCER
Volatile Organic Compounds for the Assessment of Liver Disease
Changes in Bile Acids and Microbiota in Patients With Hepatitis D Treated With Bulvertide
Liver Cancer Prevention Randomized Control Trial
Effects of Empagliflozin on Fibrosis and Cirrhosis in Chronic Hepatitis B Patients
Endoscopic Ultrasound Shear Wave Elastography Study
LITMUS Imaging Study
Safety and Effectiveness of Sulfasalazine in the Treatment of Liver Fibrosis/Cirrhosis.
Prevalence of Non-Alcoholic Fatty Liver Disease in Inflammatory Bowel Disease Patients
Endoscopic Ultrasound Shear Wave for Liver Fibrosis in MASLD Patients: The RUMIPAMBA Trial
Stem Cell Applications in Biliary Atresia Patients
Find HDV and Determine Its Status in Turkey
Global Research Initiative for Patients Screening on MASH
Reducing Non-Alcoholic Steatohepatitis